Gleevec is an inelastic crabmeat do do drugss which created a monopoly in the pharmaceutic malignant neoplastic disease drug marketplace in the recent years. Since Gleevec is a life saving drug and it has no competition, it does not verification affected by roughly of the economic conditions. Gleevecs closest hostility is still in evolution phase and there is no guarantee that it will be completed or crystalize by the Federal dose ecesis (FDA) therefore Gleevec has no fear of a challenger coming into the pharmaceutical malignant neoplastic disease drug market in the near next. Continuous studies atomic number 18 showing compromising affects of Gleevec on heart diseases besides leukemia and if okay by the FDA in the future Gleevec can be utilisation to cure heart diseases which may expands Gleevecs use and pull its expense down due to ontogenesis of demand. Gleevec is a new shopwindow of cancer drug; the primary of its kind developed to overturn cancer by turning off an enzyme that types cells to become malignant and multiply. The U.S. Food and Drug Administration approved Gleevec (imatinib mesylate, or STI-571), in May 2001 for treating patients with three stages of inveterate myelogenous leukemia (CML). Gleevec was approved under the U.S. governments divest drug program, which provides financial incentives for the study of drugs to treat r are diseases.
benediction was based on clinical studies that demonstrated the drugs effectiveness in 90% of the patients studied. CML is a private credit line cancer in which there are too many bit etiolated ancestry cells. These cells, which dont rifle correctly, crowd out the usual white blood cells. This clogs up the bloodstream and leaves the body with no defense against infections. The cause of CML is a gene on a chromosome called the Philadelphia chromosome. The gene makes a foul protein that causes cancer in white blood cells. Gleevec works... If you unavoidableness to get a full essay, order it on our website: Ordercustompaper.com
If you want to get a full essay, wisit our page: write my paper
No comments:
Post a Comment